The U.S. government initiated a formal trade investigation into Germany’s proposed drug-pricing reforms under Section 301 of the Trade Act of 1974. This probe could result in new tariffs on German imports and escalates transatlantic tensions over healthcare spending.
The U.S. Trade Representative argues the reforms unfairly burden American commerce and reduce returns on pharmaceutical innovation. Officials stated that American patients should not bear a disproportionate share of global research and development costs.
Eli Lilly confirmed it will scale back planned investments in Germany, citing the pricing reforms as the primary driver. These strategic shifts impact major constituents of healthcare ETFs, specifically IYH and VHT.